Here is the report on why I decided to sell at $NKTR (-5.41%) decided to sell.
SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced on Tuesday that its experimental drug Rezpegaldesleukin for the treatment of atopic dermatitis has shown sustained efficacy in the 36-week maintenance phase of its Phase 2b REZOLVE-AD study. The share price of the biotech company, which is currently valued at around 754 million US dollars, has risen by over 250% in the past year, according to data from InvestingPro has risen by over 250% in the past year.
The study examined patients with moderate to severe atopic dermatitis who received either a monthly or quarterly maintenance dose after at least 50% improvement during the initial 16-week treatment phase.
According to the company, 71% and 83% of patients maintained an EASI 75 response (a 75% improvement in disease severity) with monthly and quarterly dosing of 24 µg/kg, respectively. In addition, 85% and 63% were able to maintain a validated Investigator Global Assessment Score of 0/1 (appearance-free or near appearance-free skin) with the same dosing regimens.
The data showed increasing efficacy over time, with the number of patients achieving complete freedom from appearance (EASI-100) increasing two- to five-fold from week 16 to week 52.
"These data demonstrate that recpegaldesleukin as a broadly effective Treg agonist is emerging as one of the most important mechanisms under development for the treatment of atopic dermatitis," Jonathan Silverberg, professor of dermatology at the George Washington University School of Medicine and Health Sciences, said in the press release.
The safety profile was consistent with previous results, with injection site reactions being the most common adverse effect. The discontinuation rate due to adverse events was 3.5% for all patients.
Rezpegaldesleukin works by stimulating regulatory T cells to restore the balance of the immune system. The FDA had previously granted fast-track status to the compound for the treatment of atopic dermatitis and alopecia areata.
Based on these results, Nektar plans to advance Rezpegaldesleukin into Phase 3 trials with the goal of submitting a Biologics License Application in 2029. Although the company's balance sheet shows that it has more cash than debt, data from InvestingPro indicate that it is rapidly consuming liquidity - a critical factor given the long development time. Analyst price targets indicate significant upside potential, ranging from $102 to $135 per share. Nektar's next quarterly report is expected on February 25.